Ci‑Ca therapy
Think Ci‑Ca therapy.
Your responsibility in good hands.
Your professional world is changing constantly. You appreciate technologies that are continuously evolving and help you to provide your patients with even better therapy. We would like to support you by offering a comprehensive approach for citrate anticoagulation-based CKRT: Ci‑Ca therapy.
At a time when healthcare professionals are increasingly involved in non-caregiving activities such as administration, treatment documentation and medication preparation, there is a growing need for reliable, one-stop solutions which decrease the strain on the ICU staff.
Fresenius Medical Care is the first provider to offer a complete range of Ci‑Ca therapy products from a single source, supporting healthcare professionals to focus on the essential: patient care.
Regional citrate anticoagulation enables patient treatment with less bleeding complications and less filter clotting compared to heparin CKRT.1‑3 As one option to implement regional citrate anticoagulation, Ci‑Ca therapy is an effective and reliable alternative to heparin4‑11 and lets your ICU staff focus more on the patient and less on handling issues.5,11
Participate in our experience: Fresenius Medical Care was the first to offer a completely machine integrated Ci‑Ca regional citrate anticoagulation. Healthcare professionals in more than 30 countries have already gained experience with Ci‑Ca therapy and appreciate its reliable and easy application in clinical routines.5,6
Our proven citrate protocol is fully integrated in the multiFiltratePRO and reflected in all our Ci‑Ca products.
Think reliable.
Think Ci‑Ca therapy.
Think smart.
Think Ci‑Ca therapy.
Think partner.
Think Ci‑Ca therapy.
Think value‑based.
Think Ci‑Ca therapy.
1 Tsujimoto H et al. Cochrane Database Syst Rev. 2020; 12(12):CD012467
2 KDIGO Clinical Practice Guideline for Acute Kidney Injury., Kidney Int Suppl 2012; 2:1‑138
3 Bai M et al. Intensive Care Med 2015; 41:2098‑2110
4 Bianchi NA et al. Blood Purif 2020; 49:567‑575
5 Kalb R et al. Ther Apher Dial 2013; 17:202‑212
6 Morgera et al. Crit Care Med 2009;37:2018‑2024
7 Slowinski T et al. Crit Care 2015; 19:349
8 Link A et al. Crit Care 2012; 16:R97
9 Huguet M et al. Int J Artif Organs 2017; 40:676‑682
10 Hafner S et al. J Intensive Care 2015; 3:35
11 Houllé-Veyssière et al. Intensive Crit Care Nurs 2016; 36:35‑41
12 Hetzel GR et al. Nephrol Dial Transpl 2011; 26:232‑239
13 Zarbock A et al. JAMA 2020; 324:1629‑1639
14 Li L et al. Semin Dial 2021; 34:209‑217
15 Dalhuisen A et al. Neth J Crit Care 2017; 25:122‑127
16 Kindgen-Milles D et al. Curr Opin Crit Care 2018; 24:450‑454
17 Huang Z et al. Int J Artif Organs 2008, 31:525‑534
18 Nalesso F et al. J Clin Med 2020; 9:1529